Methotrexate topical - MediQuest Therapeutics

Drug Profile

Methotrexate topical - MediQuest Therapeutics

Alternative Names: MQX-5902; MQX-5904; MQX-5906

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator MediQuest Therapeutics
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 17 Sep 2015 No recent reports on development identified - Phase-II for Psoriasis in United Kingdom (Topical)
  • 28 Aug 2012 Methotrexate topical - MediQuest Therapeutics is available for licensing as of 28 Aug 2012. http://www.mqti.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top